Liposomal Irinotecan Regimen for Durable Pancreatic Cancer Response

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a critical need for improved therapies to prolong the lives of patients with advanced pancreatic cancer, which often becomes resistant to current treatments, with limited screening tools and a high mortality rate due to the absence of durable therapies.

Innovation Solution

Administering liposomal irinotecan, in combination with 5-fluorouracil and leucovorin, following a specific clinical dosage regimen, tailored for patients with or without the UGT1A1*28 allele, to treat pancreatic cancer, particularly after disease progression following gemcitabine-based therapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If standard chemotherapy regimens (5-FU, gemcitabine, FOLFIRI, FOLFIRINOX) are used to treat pancreatic cancer, then survival is prolonged to some extent, but the cancer develops resistance and survival benefit is limited

Engineering Contradiction:

Improvesurvival durationVSAvoidtherapy durability

Core Design Contradiction:

Duration of action of moving objectVSReliability

Solution Approach 1:

The patent modifies the pharmacokinetic parameters of irinotecan by formulating it as a liposomal suspension, which changes the drug's delivery characteristics, half-life, and concentration profile. This parameter change enables the drug to achieve sustained therapeutic levels in pancreatic tumors while reducing resistance development, directly addressing the limitation of standard chemotherapy durability.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite formulation by combining irinotecan with liposomal carriers, resulting in a novel drug delivery system that integrates the cytotoxic properties of irinotecan with the targeted delivery capabilities of liposomes. This composite approach enhances therapy durability by protecting the drug from rapid clearance and improving tumor penetration.

Inventive Principle:

Principle #40Composite materials

2Productivity

If irinotecan is administered as conventional formulation, then tumor growth is inhibited, but significant toxicity is observed and drug resistance develops

Engineering Contradiction:

Improvetumor growth inhibitionVSAvoidtoxicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The liposomal formulation acts as an intermediary carrier that transports irinotecan to tumor cells through the EPR effect. This intermediary system enables the drug to reach its target more effectively while reducing off-target toxicity, as the liposomes protect the drug from premature release and systemic distribution to healthy tissues.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The liposomal irinotecan formulation achieves local accumulation in pancreatic tumors through enhanced permeability and retention effects, concentrating the drug at the tumor site while minimizing systemic exposure. This local quality enhancement improves the therapeutic index by maintaining high tumor penetration while reducing overall toxicity.

Inventive Principle:

Principle #3Local quality

3Productivity

If combination therapy with multiple chemotherapies is used, then treatment effectiveness increases, but complexity of treatment regimen and toxicity accumulate

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidregimen complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent segments the chemotherapy approach by focusing on a single optimized agent (irinotecan) delivered through a specialized liposomal formulation, rather than combining multiple drugs. This segmentation simplifies the regimen while maintaining effectiveness, as the liposomal delivery system provides the targeted penetration and sustained release that would otherwise require multiple agents to achieve.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination therapy significantly prolongs survival and improves chemotherapy outcomes by increasing tumor vascularity and reducing toxicity, offering therapeutic synergy and effective treatment options for metastatic pancreatic adenocarcinoma.

Implementation Method 1

The combination therapy significantly prolongs survival and improves chemotherapy outcomes by increasing tumor vascularity

Methodology Applied

Scientific EffectEnhanced permeability and retention effect:

Implementation Method 2

The combination therapy significantly prolongs survival and improves chemotherapy outcomes by increasing tumor vascularity and reducing toxicity

Methodology Applied

Scientific EffectTargeted delivery:

Data Source

PatentUS20260000666A1Methods For Treating Pancreatic Cancer Using Combination Therapies

Publication Date: 2026.01.01 IPSEN BIOPHARM LTD

AI summary

Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.